From: The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis
Study | Number of patients | Number (n)/% of biopsied patients |
---|---|---|
Pirfenidone | 107 | - pirfenidone: n = 15/21% |
Azuma et al., AJRCCM 2005 | - placebo: n = 8/23% | |
Pirfenidone | 267 | - high dose: n = 26/24% |
Taniguchi et al., Eur Respir J 2010 | - low dose: n = 16/29% | |
- placebo: n = 28/27% | ||
Pirfenidone | CAPACITY I | CAPACITY I |
Noble et al., Lancet 2011 | 435 | - 1197 mg: n = 32/37% |
CAPACITY I | CAPACITY II | - 2403 mg: n = 86/49% |
CAPACITY II | 334 | - placebo: n = 85/49% CAPACITY II |
- pirfenidone: n = 94/55% | ||
- placebo: n = 94/54% | ||
Triple-therapy | 155 | - triple therapy: n = 38/48% |
Demedts et al., NEJM 2005 | - control: n = 35/47% | |
IFIGENIA | - excluded patients: n =24/89% | |
Interferon gamma-1b | 330 | - IFN-γ-1b: 62% |
Raghu et al., NEJM 2004 | - placebo: 67% | |
Interferon gamma-1b | 826 | - IFN-γ-1b: n = 305/55% |
King et al., | - placebo n = 151/55% | |
Lancet 2009 | ||
INSPIRE | ||
Bosentan | 158 | - bosentan: 68% |
King et al., | - placebo: 60% | |
AJRCCM 2008 | ||
BUILD-1 | ||
Imatinib | 119 | - imatinib: n = 25/42% |
Daniels et al., | - placebo: n = 29/48% | |
AJRCCM 2010 | ||
Etanercept | 88 | - etanercept: n = 28/46% |
Raghu et al., | - placebo: n = 23/41% | |
AJRCCM 2008 | ||
Triple-kinase | 432 | - placebo: n = 19/22% |
Richeldi et al., |  | - 50 mg × 1: n = 25/29% |
NEJM 2011 |  | - 50 mg × 2: n = 27/31% |
 |  | - 100 mg × 2: n = 20/23% |
 |  | - 150 mg × 2: n = 29/34% |